Shuttle Pharmaceuticals Holdings, Inc. - common stock (SHPH)
2.0400
-0.1000 (-4.67%)
NASDAQ · Last Trade: Jan 21st, 4:54 PM EST
Detailed Quote
Previous Close
2.140
Open
1.960
Bid
2.000
Ask
2.060
Day's Range
1.800 - 2.200
52 Week Range
1.260 - 25.25
Volume
1,554,521
Market Cap
2.18M
PE Ratio (TTM)
-0.4056
EPS (TTM)
-5.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
7,463,407
Chart
About Shuttle Pharmaceuticals Holdings, Inc. - common stock (SHPH)
Shuttle Pharmaceuticals Holdings, Inc. is a biotechnology company focused on advancing innovative solutions for cancer treatment through its development of novel therapeutics. The company specializes in research aimed at improving the effectiveness of existing cancer therapies, particularly by enhancing the response of cancer cells to radiation and chemotherapy. Shuttle Pharmaceuticals is dedicated to leveraging scientific advancements to create new medications that enhance patient outcomes and quality of life, demonstrating its commitment to addressing significant challenges in oncology. Through its proprietary technologies and drug development programs, the company strives to bring transformative therapies to market that can better support cancer patients and their healthcare providers. Read More
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced...
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
In the laboratories of modern medicine, time is the ultimate constraint. Every discovery competes against the clock: the years it takes to identify a viable molecule, the millions consumed by failed trials, and the patients waiting while the process plays out. The cost of delay is measured not only in dollars but also in lives.
Gaithersburg, Maryland--(Newsfile Corp. - November 3, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today...
ROCKVILLE, MD / ACCESS Newswire / October 22, 2025 / Every generation has its frontier. For the last century, medicine's remained molecular: genes, proteins, receptors, the invisible mechanics of life. Today, that frontier is shifting again. The next wave isn't about what we can see under a microscope. It's about what we can teach a machine to see for us.
ROCKVILLE, MD / ACCESS Newswire / October 22, 2025 / Artificial intelligence has reshaped nearly every industry, but drug discovery has always been its toughest proving ground. Molecules don't follow patterns; they twist, bind, and defy prediction, humbling even the smartest algorithms.
ROCKVILLE, MD / ACCESS Newswire / October 21, 2025 / Radiation therapy has always been the heavyweight of cancer treatment. It works, but it's a brute. It blasts cancer cells, hoping the good ones can withstand the damage. For decades, that was the tradeoff. Precision meant power, and power meant pain, along with a whole lot of side effects. But what if the next evolution of radiation wasn't about turning up the dose, but about turning up the intelligence?
